- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...

ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...

SC administration of VELCADE also demonstrated acceptable local tolerability. Only 6 percent of patients had at least one SC local injection site reaction reported as an adverse event, with the most ...

May 19, 2003 — Editor's Note: On May 12, the U.S. Food and Drug Administration (FDA) approved Velcade (bortezomib), the first drug in its class of proteasome inhibitors, for the treatment of patients ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug ...

-- Data on use of VELCADE in follicular lymphoma to be featured in additional oral presentation -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today announced abstracts ...

Millennium and its parent company Takeda announced that the FDA has approved Velcade (bortezomib) for subcutaneous administration in the management of multiple myeloma and mantle cell lymphoma after ...

Millennium Pharmaceuticals reported results from two Phase 3 studies of Velcade (bortezomib injection); the first study compared Velcade and rituximab to rituximab monotherapy for the treatment of ...

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to ...

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...